AS01B |
|
Vaxjo ID |
504 |
|
Vaccine Adjuvant Name |
AS01B |
|
Adjuvant VO ID |
VO_0005358
|
|
Description |
A combination vaccine adjuvant includes 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) purified from plant extract Quillaja saponaria Molina, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution. |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
United States |
|
Host Species for Testing |
Human |
|
Components |
TLR4 ligand 3D MPL and QS-21 saponin |
|
Dosage |
500 uL |
|
Function |
Type: combination vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). |
| Related Vaccine(s) |
|
| References |
FDA: Common Ingredients in FDA-Approved Vaccines [https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-fda-approved-vaccines]
NCT01157897: Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults [Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults]
|
